Skip to main content
SpringerLink
Log in

Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c‐erbB and retinoic acid receptor expression in MCF‐7 breast cancer cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Nuclear steroid/thyroid/retinoid receptors and c‐erbB membrane receptor tyrosine kinases control epithelial growth and differentiation. Retinoid receptors can dimerize with the vitamin D receptor, the glucocorticoid receptor or the thyroid receptor. Furthermore, multiple c‐erbB receptor dimers have been identified. It has been shown that some of these receptor pathways communicate with each other via cross‐connected regulatory networks. Molecular interactions between retinoid receptors or estrogen receptors (ER) and c‐erbB‐2, and between ER and retinoic acid receptor(RAR)‐α have been reported. Here, we demonstrate the effects of steroids/thyroids/retinoids and of activators of protein kinase A (forskolin, Forsk) and C (12‐O‐tetradecanoylphorbol‐13‐acetate, TPA), on growth and expression of c‐erbB and RARs in MCF‐7 breast cancer cells, which contain high levels of RAR‐α and ‐γ, and which express significant amounts of c‐erbB‐2 and ‐3. All trans‐retinoic acid (tRA), the anti‐estrogen ICI 182 780 (ICI), Forsk and TPA reduced, whereas triiodothyronine and 17β‐estradiol (E2) stimulated cell growth. Flow cytometry revealed that tRA and E2 reduced c‐erbB‐2 and ‐3, whereas tamoxifen, Forsk and TPA up‐regulatedc‐erbB‐2. c‐erbB‐3 was co‐regulated with c‐erbB‐2. Northern analysis demonstrated that RAR‐α was down‐regulated by dexamethasone, ICI, and TPA, whereas vitamin D3 and E2 up‐regulated RAR‐α. RAR‐γ expression was less responsive to such treatment, being reduced only by ICI and Forsk. These data indicate that nuclear receptor and protein kinase signaling communicate with each other and control the expression of RARs and c‐erbB receptors. Efficient growth control requires the coordinated interplay of both receptor systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carraway KL III, Cantley LC: A neu acquaintance for erbB-3 and erbB-4: a role for receptor heterodimerization in growth signaling. Cell 78: 5–8, 1994

    Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  3. Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F: Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J Cancer Res Clin Oncol 116: 503–506, 1990

    Google Scholar 

  4. Decensi A, Formelli F, Torrisi R, Costa A: Breast cancer chemoprevention: studies with 4–HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biochem Suppl 17G: 226–233, 1993

    Google Scholar 

  5. Moon RC, Mehta RG, Detrisac CJ: Retinoids as chemopreventive agents for breast cancer. Cancer Detect Prev 16: 73–79, 1992

    Google Scholar 

  6. Durand B, Saunders M, Leroy P, Leid M, Chambon P: Alltrans and 9–cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DRl and DR2 repeated motifs. Cell 71: 73–85, 1992

    Google Scholar 

  7. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J-Y, Staub A, Garner JM, Mader S, Chambon P: Purification, Cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68: 377–395, 1992

    Google Scholar 

  8. Nagaya T, Kopp P, Kitajima K, Jameson JL, Sco H: Second zinc finger mutants of thyroid hormone receptor selectively preserve DNA binding and heterodimerization but eliminate transcriptional activation. Biochem Biophys Res Commun 222: 524–530, 1996

    Google Scholar 

  9. Schrader M, Bendik I, Becker-Andre M, Carlberg C: Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268: 17830–17836, 1993

    Google Scholar 

  10. Yen PM, Sugawara A, Chin WW: Triiodothyronine (T3) differentially affects T3–receptor/retinoic acid receptor and T3–receptor/retinoid X receptor heterodimer binding to DNA. J Biol Chem 267: 23248–23252, 1992

    Google Scholar 

  11. Yu VC, Delsert C, Andersen B, Holloway JM, Devary OV, Näär AM, Kim SY, Boutin JM, Glass CK, Rosenfield MG: RXRb: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell 67: 1251–1266, 1991

    Google Scholar 

  12. Grunt T, Saceda M, Martin M, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittnch C: Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560–567, 1995

    Google Scholar 

  13. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446, 1995

    Google Scholar 

  14. Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–3951, 1990

    Google Scholar 

  15. Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624–6629, 1992

    Google Scholar 

  16. Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R, Martin MB: Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology 137: 4322–4330, 1996

    Google Scholar 

  17. Tang CK, Perez C, Grunt TW, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350–3358, 1996

    Google Scholar 

  18. Bacus SS, Kiguchi K, Chin D, King CR, Hubermann E: Differentiation of human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinog 3: 350–362, 1990

    Google Scholar 

  19. Flicker S, Schneider SM, Offterdinger M, Dittrich E, Valenta R, Huber H, Dittrich C, Grunt TW: c-erbB receptor tyrosine kinase signaling pathways control the expression of retinoid/steroid receptors in breast cancer cells. Cancer Lett 115: 63–72, 1997

    Google Scholar 

  20. Grunt TW, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, Huber H: Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Brit J Cancer 78: 79–87, 1998

    Google Scholar 

  21. Butler WB, Fontana JA: Responses to retinoic acid of tamoxifen-sensitive and-resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52: 6164–6167, 1992

    Google Scholar 

  22. Rishi AK, Shao ZM, Baumann RG, Li XS, Sheikh MS, Kimura S, Bashirelahi N, Fontana JA: Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Res 55: 4999–5006, 1995

    Google Scholar 

  23. Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, Sutherland RL, Clarke CL: Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res 53: 5940–5945, 1993

    Google Scholar 

  24. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Miller WH Jr:9–cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 54: 6549–6556, 1994

    Google Scholar 

  25. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA: Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 57: 2642–2650, 1997

    Google Scholar 

  26. Fontana X, Ferrari P, Namer M, Peysson R, Salanon C, Bussiere F: C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 14: 2099–2104, 1994

    Google Scholar 

  27. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90: 37–42, 1998

    Google Scholar 

  28. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38: 57–66. 1996

    Google Scholar 

  29. Pellegrini R, Mariotti A, Tagliabue E, Bressan R. Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnaghi MI, Ménard S: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4–hydroxyphenyl)retinamide. Cell Growth Differ 6: 863–869, 1995

    Google Scholar 

  30. Rock CL, Saxe GA, Ruffin MT 4th, August DA, Schottenfeld D: Carotenoids, vitamin A, and estrogen receptor status in breast cancer. Nutr Cancer 25: 281–296, 1996

    Google Scholar 

  31. Stoll BA: Breast cancer: further metabolic-endocrine risk markers? Brit J Cancer 76: 1652–1654, 1997

    Google Scholar 

  32. Harant H, Lindley I, Uthman A, Ballaun C, Krupitza G, Grunt T, Huber H, Dittrich C: Regulation of interleukin-8 gene expression by all-trans retinoic acid. Biochem Biophys Res Commun 210: 898–906, 1995

    Google Scholar 

  33. Demirpence E, Balaguer P, Trousse F, Nicolas JC, Pons M, Gagne D: Antiestrogenic effects of all-trans retinoic acid and 1,25–dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. Cancer Res 54: 1458–1464, 1994

    Google Scholar 

  34. Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu B, Zhang XK: Inhibition of trans-retinoic acid resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 17: 6598–6608, 1997

    Google Scholar 

  35. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 58: 478–484, 1998

    Google Scholar 

  36. Bates NP, Hurst HC: An intron 1 enhancer element mediates oestrogen-induced suppression of erbB-2 expression. Oncogene 15: 473–481, 1997

    Google Scholar 

  37. Dobashi K, Weiner DB, Greene MI: Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. DNA 8: 723–732, 1989

    Google Scholar 

  38. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE: erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56: 522–528, 1994

    Google Scholar 

  39. Roman SD, Clarke CL, Hall RE, Alexander JE, Sutherland RL: Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52: 2236–2242, 1992

    Google Scholar 

  40. Yen A, Roberson MS, Varvayanis S, Lee AT: Retinoic acid induced mitogen-activated protein (MAP)/extracellular signalregulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58: 3163–3172, 1998

    Google Scholar 

  41. Rochette-Egly C, Oulad-Abdelghani M, Staub A, Pfister V, Scheuer I, Chambon P, Gaub MP: Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Mol Endocrinol 9: 860–871, 1995

    Google Scholar 

  42. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P: Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 90: 97–107, 1997

    Google Scholar 

  43. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harley E, Graupner G, Lu XP, Pfahl M: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372: 107–111, 1994

    Google Scholar 

  44. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone U, Bolado J, Verma IM, Evans RM: Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci USA 88: 6092–6096, 1991

    Google Scholar 

  45. Martin MB, Garcia-Morales P, Stoica A, Solomon HB, Pierce M, Katz D, Zhang S, Danielsen M, Saceda M: Effects of 12–O-tetradecanoylphorbol-13–acetate on estrogen receptor activity in MCF-7 cells. J Biol Chem 270: 25244–25251, 1995

    Google Scholar 

  46. De-Launoit Y, Kiss R: Influence of L-thyrexine, Ltriiodothyronine, thyroid stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer cells. In Vitro Cell Dev Biol 25: 585–591, 1989

    Google Scholar 

  47. Guilbaud NF, Gas N, Dupont MA, Valette A: Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145: 162–167, 1990

    Google Scholar 

  48. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM: Retinoic acid inhibition of cell cycle progression inMCF-7 human breast cancer cells. Exp Cell Res 234: 293–299, 1997

    Google Scholar 

  49. De Vincenzo R, Scambia G, Benedetti-Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S, Mancuso S: Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast cancer cells. Int J Cancer 68: 340–348, 1996

    Google Scholar 

  50. Darbon JM, Valette A, Jozan S, Issandou M, Bayard F: Dissociation between protein kinase C content and biological responsiveness to phorbol esters in tumor promotersensitive (MCF-7) and resistant (Rph-4) cells. Biochem Pharmacol 40: 1785–1792, 1990

    Google Scholar 

  51. Brunner N, Bronzert D, Vindelov LL, Rygaard K, Spang-Thomsen M, Lippman ME: Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49: 1515–1520, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Cell Growth and Differentiation, Division of Oncology, Department of Internal Medicine I, University of Vienna, Vienna, Austria

    Sonja M. Schneider, Martin Offterdinger, Heinz Huber & Thomas W. Grunt

Authors
  1. Sonja M. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Offterdinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas W. Grunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, S.M., Offterdinger, M., Huber, H. et al. Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c‐erbB and retinoic acid receptor expression in MCF‐7 breast cancer cells. Breast Cancer Res Treat 58, 171–181 (1999). https://doi.org/10.1023/A:1006377006816

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006377006816

Search

Navigation